Therapeutic effect of intranasal evaporative cooling in @entity1 with XXXX : a pilot study.

@entity1 @entity455 @entity2704 @entity2794 @entity158 @entity10
BACKGROUND: Cryotherapy is the most common non-pharmacological @entity158 -relieving method. The aim of this pilot study was to ascertain whether intranasal evaporative cooling may be an effective intervention in an acute @entity2704 attack. Studies have previously demonstrated effectiveness of a variety of cryotherapy approaches. Intranasal evaporative cooling due to @entity455 from nasal and paranasal mucous membranes to the dura mater, thereby providing an excellent anatomical basis for the cooling processes. METHODS: We conducted a prospective, open-label, observational, pilot study. Twenty-eight @entity1 who satisfied the International Classification of @entity2794 (ICHD 2) diagnostic criteria for @entity2704 were recruited. A total of 20 treatments were administered in 15 @entity1 . All @entity1 provided @entity158 severity scores and @entity2704 severity scores (based on a 0-10 visual analogue scale, [VAS]). RESULTS: Out of the 20 treatments, intranasal evaporative cooling rendered @entity1 ' @entity158 and symptoms free immediately after treatment, in 8 of the treatments (40%), a further 10 treatments (50%) resulted in partial @entity158 relief ( @entity10 reduced from severe or moderate to mild) and partial symptoms relief. At 2 hours, 9 treatments (45%) provided full @entity158 and symptoms relief, with a further 9 treatments (45%) resulting in partial @entity158 and symptoms relief. At 24 hours, 10 treatments (50%) resulted in @entity1 reporting @entity158 and symptom freedom and 3 (15%) provided partial @entity158 relief. In summary 13 @entity1 (87%) had benefit from the treatment within 2 hours that was sustained at 24 hours. CONCLUSIONS: Intranasal evaporative cooling gave considerable benefit to @entity1 with @entity2704 , improving @entity10 severity and @entity2704 . A further randomised, placebo controlled, double blinded, parallel clinical trial is required to further investigate the potential of this application.Trial registration: Clinicaltrials.gov registered trial, ClinicalTrials.gov Identifier: NCT01898455.
